This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceuticalcompanies to focus their R&D investment.
Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.
As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.
BOSTON – Nov 1, 2022 – Fuld & Company, a fast-growing research, analytics, and advisory business, today announced the appointment of Brad Thompson to the role of Advisory Board Member. About Fuld & Company. www.fuld.com.
In this context, several industry players have demonstrated high inclination towards supporting and advancing the development of next generation RNA-based therapeutics, vaccine and technologies. The below given figure provides an illustrative summary of the benefits of next generation RNA-based vaccines and RNA-based therapeutics market.
Was ranked the highest among the list of companies developing Cell & Gene therapy, followed by Novartis with a revenue of $50.54B and Spark Therapeutics with a revenue of $49.27B PharmaShots brings an informative report on the Top 20 Cell and Gene Therapy Companies based on the total Revenue generated in the year 2022 Total Revenue: $0.5M
Leela Barham and Neil Grubert look back at what was expected for market access in 2021 and look ahead at what 2022 could hold. Will all the efforts to speed up market access and ensure that the UK remains attractive to the life sciences industry post-Brexit pay off in 2022? 2022 will see both sides assessing scheme performance.
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceuticalcompanies in 2023 are assessed.
RSV researchers at major pharmaceuticalcompanies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. per 100,000 people were hospitalised for RSV-related reasons in the 2022–23 RSV season. per 100,000.
Below you can find all the winners from the 2022 Excellence Awards which celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognise the people and companies that are driving change. The company has founded a non-commercial Global Health Unit to meet these goals.
In 2022, CMS reevaluated 505(b)(2) drugs in relation to section 1847A of the Social Security Act (SSA). In 2022, based upon a complaint filed by a pharmaceuticalcompany, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. “In This went into effect in January 2022.”
The company's mRNA platform comprises advances across three components, i.e., mRNA, delivery, and the manufacturing process. Moderna's 2022 revenue increased by 0.04% vs. 2021. Merck KGaA's 2022 revenue depicted an inclination of 6.56% vs. 2021. Novo's 2022 revenue increased by 0.18% vs. 2021.
This Q&A covers the key developments in pharmaceutical microbiology in 2022, featuring insight from pharmaceutical microbiology experts: Dr Tim Sandle, Head of Microbiology, Bio Products Laboratory Limited. Regulation, particularly Annex 1, was identified as a key focus for 2022.
In recent years, leading pharmaceuticalcompanies, such as Sanofi, successfully launched smart factory programmes. About the authors Shidong Shi, PhD Head of Upstream Process Development, Altruist Biologics Dr Shi joined Altruist Biologics in 2022 in his current role. 2022; 78:102828. 2022; 414(2):969-991.
Once lockdown measures eased and Covid-19 vaccines and boosters became available, the industry anticipated a significant recovery in the market and in the number of deals. In 2022, Russia’s war on Ukraine struck the supply chain, eventually slowing manufacturing and causing shortages for multiple pharmaceuticalcompanies.
In the 1990s, generic pharmaceuticalcompanies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. Despite having large biopharmaceutical companies on home ground, the UK and France experienced major shortages and supply chain issues.
However, two successive years of unusually high branded medicine sales figures, following the COVID-19 pandemic and a major post-lockdown surge in demand, have distorted the original model, causing a massive hike in payback rates, first capped at 15% in 2022, then jumping to 26.5% In 2022, a proposed payback figure of 19.1%
Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait times and higher prices for thousands of products. Automation can be such a solution. Automation can be such a solution.
mRNA-based therapeutics and vaccines have emerged as a promising alternative to conventional treatment approaches. Till date, four mRNA-based vaccines have received approval for the treatment of COVID-19, while a number of such candidates are being evaluated as potential therapies.
2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward. Wed, 11/02/2022 - 07:32. 2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward. 2 November 2022. Pfizer “cleared runway to allow for large-scale vaccine manufacturing before we had a product!” iSpeak Blog.
Pharmaceuticalcompanies such as Sanofi and AstraZeneca are currently conducting several high-potential clinical development programmes in oncology in collaboration with Innate Pharma. Detailed results from COAST were published in the Journal of Clinical Oncology in 2022.
… Pharmaceuticalcompanies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. A Or you may want to take stock of your life. But be safe. Enjoy, and see you soon.
Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 billion, the highest level since tracking of funding began in 2005 and 20% more than what was seen in 2022. Just 9% came from the private sector, such as pharmaceuticalcompanies.
Boehringer Ingelheim is acquiring Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF), boosting its immuno-oncology portfolio. There were a “record number of immuno-oncology approvals” in 2022, with 10 new innovative drugs being approved.
To ensure people in LMICs have access to new and innovative medicines and vaccines as soon as possible after launch, companies need to have an access plan in place for products in the pipeline from at least Phase II of R&D. The research showed 83 percent of pharmaceuticalcompanies are putting more strategies in place.
The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies for their efforts to improve delivery of medicines to lower income countries – sees GSK retain the number one position, newly joined by Johnson & Johnson in second and AstraZeneca in third. Jayasree Iyer.
2022 Evidence & Opportunity: Impact of Life Sciences in North Carolina.” Published November 2022. Surrounded by universities and community colleges with life sciences programs, companies in RTP were able to access highly skilled graduates, increasing employment in the state. AAV gene therapy plant in 2022.
Pharmaceuticalcompanies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. Press Release, March 2, 2022. link] Cleveland Clinic. Punctal Plugs. ClevelandClinic.org (accessed June 20, 2025). Ophthalmol.
Even with the vaccine roll-out, further waves of COVID infection and lockdowns mean these vital drivers of launch performance remain impacted in 2021, and even beyond. Achievement, meaning commercial performance in the context of sales uptake, as measured by the IQVIA sales audits.
With the adoption of digital technologies gaining traction in many industries, pharmaceuticalcompanies must take advantage of digitalisation within its research and development (R&D) sector.
BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate a single dose mRNA-based combination vaccine candidate against influenza and COVID-19 – a novel combination approach to help protect individuals against two severe respiratory viral diseases in one dose.
model is a holistic approach to incorporate the same strategy to life science and pharmaceuticalcompanies. A globally fast-growing, and largest pharmaceuticalcompany in the world was created through a merger between Pfizer and Pharmacia. Model: Inspired by the industry 4.0 model, the pharma 4.0 compared to 2015.
Check out our intuitive article on “8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry To get a full trend report of 60+ Biopharma companies globally in 2022-23 email us at connect@pharmashots.com. The pharmaceutical industry is an integral part of the healthcare system.
Check out our intuitive article on “8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry To get a full trend report of 60+ Biopharma companies globally in 2022-23 email us at connect@pharmashots.com. The pharmaceutical industry is an integral part of the healthcare system.
It disheartens us to discover that neither pharmaceuticalcompanies nor public health authorities are willing to fund high-quality research to find out if cimetidine really can shorten the duration of a painful shingles attack. To date, however, such studies do not appear to have been conducted. Tagamet for Warts?
Frontiers Health 2022. Influencer culture has well and truly taken over the internet, with numerous benefits on offer for pharmaceuticalcompanies in the healthcare influencer space. Company profile: Vinehealth. Case study: Syneos Health and VBI Vaccines. Read Deep Dive: Digital Health 2022 in full.
The use of artificial intelligence and machine learning will also increase in 2021 and is expected to become an $8 billion industry by 2022. The pharmaceutical industry is making it a high priority to be transparent with their audience and help their patients feel as comfortable as possible while getting the care they need.
ODAIA will use the latest investment to further advance its artificial intelligence (AI)-powered product offerings, allowing the pharma companies to deliver various life changing therapies to the patients faster.
1 Kenya, for example, entered the pandemic with no human vaccines manufacturing facility and established the BioVax institute for local vaccine manufacture with a major plant investment starting in 2023. Regulatory divergence became apparent in 2022 and could increase in 2023. Pharma’s starting to wake up to this.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content